DOSE CAP FOR NIMESULIDE: WHAT THE GOVERNMENT'S BAN ON 'HIGH-STRENGTH' TABLETS MEANS FOR PATIENTS

This is not just a single-drug story; it's a signal of dose rationalization—the regulator pushing back on “more milligrams equals better relief” marketing.

- TDG NETWORK

India has prohibited the manufacture, sale, and distribution of all immediate-release oral formulations of nimesulide that contain more than 100 mg.

The public-facing headline is simple—“high-dose nimesulide pills banned”—but the intent is more specific: the regulator is drawing a hard line on strength and release pattern for a painkiller that has long carried safety concerns, especially around the liver.

WHAT EXACTLY IS BANNED?

The notification applies to oral, immediate-release products (tablets/capsules, etc.) that contain nimesulide above 100 mg per unit dose. Immediate-release matters because it delivers the drug quickly, creating higher peak exposure than a slow-release design.